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ABSTRACT
Over the last 50 years, mouse models of bone marrow transplantation have provided the critical links between
graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) pathophysiology and clinical practice.
The initial insight from mouse models that GVHD and GVL were T cell dependent has long been confirmed
clinically. More recent translations from mouse models have included the important role of inflammatory cyto-
kines in GVHD. Newly developed concepts relating to the ability of antigen presenting cell (APC) and T cell
subsets to mediate GVHD now promise significant clinical advances. The ability to use knockout and transgenic
approaches to dissect mechanisms of GVHD and GVL mean that mouse systems will continue as the predom-
inant preclinical platform. The basic transplant approach in these models, coupled with modern ‘‘real-time’’
immunologic imaging of GVHD and GVL is discussed.
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Historic Perspectives
Bone marrow transplantation (BMT) was con-
ceived in the early 1950s out of rodent studies focusing
on the effects of radiation. These now classical exper-
iments noted that shielding of the spleen, or infusion of
bone marrow from a ‘‘donor animal’’ could protect an-
imals from lethality [1,2]. Interestingly, this protection
was initially thought to be because of the transfer of
a humoral factor until subsequent chromosomal anal-
ysis confirmed the engraftment of donor cells in 1956
[3]. Even at this time, the presence of a graft-versus-
leukemia (GVL) effect was mooted [4]. A report of
clinical transplantation followed a year later by E.
Donnel Thomas and colleagues [5], and the field was
born. Over the subsequent decade the introduction
of rudimentary tissue typing paved the way for the
classical murine studies of Korngold and Sprent [6,7]
in the 1970s, which confirmed the T cell dependence
of GVHD. Indeed, much of our current understanding
of BMT has its origin in their subsequent studies that
determined the role of T cell subsets in GVHD across
various MHC [8] and minor histocompatibility (HA)
mismatches [9].Mouse Models of GVHD
MHC mismatched or matched. Current murine
models of BMT can be broadly grouped into those in
which GVHD is directed to MHC (class I, class II, or
usually both) or to isolated multiple minor HA alone.
Although multiple minor HA mismatches also exist in
the former, their impact is usually limited relative to
that induced by full MHC disparities. The GVHD
that develops in response to a full (class I and II)
MHC disparity is dependent primarily on CD4 T
cells, although CD8 T cells can provide additive pa-
thology. These systems, by virtue of their CD4 depen-
dence, result in an inflammatory ‘‘cytokine storm,’’
capable of inducing GVHD in target tissues without
the requirement for cognate T cell interaction with
MHC on tissue [10]. The BMT models in which
GVHD is directed to mutated class I (bm1) or class
II (bm12) MHC antigens in isolation represent well-
utilized systems where GVHD is mediated only by
CD8 or CD4 T cells, respectively. The parent to F1
models (eg, B6 / B6D2F1) offer the advantage of
eliminating T cell-dependent host-versus-graft rejec-
tion responses (NK-dependent ‘‘hybrid resistance’’
remain), and so are particularly useful if one is129
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(eg, comparing the intensity of conditioning regimes
on GVHD severity independent of differential en-
graftment kinetics) [11]. The induction of GVHD to
multiple minor HA results in a process where either
CD8 T cells, CD4 T cells, or both may play a role in
disease [9]. In contrast to CD4-dependent GVHD,
CD8 T cells induce GVHD primarily by their cyto-
lytic machinery, which requires the TCR to engage
MHC on target tissue [10]. Importantly, these CD4
versus CD8-dependent GVHD models will have dif-
fering requirements for antigen presentation. Either
host or donor antigen-presenting cells (APC) will be
able to initiate CD4-dependent GVHD [12], whereas
only host APC will induce GVHD in CD8-dependent
systems [13]. Although the minor HA disparate sys-
tems may be the most appropriate models of clinical
BMT, the MHC disparate systems can also induce
the full spectrum of clinically relevant GVHD while
permitting greater dissection of immunologic mecha-
nisms because of the enhanced ability to measure
immunologic pathways of GVHD both in vivo and
ex vivo. Thus, it is critical from the outset to under-
stand what questions are being asked so that the
most relevant BMT model can be chosen (summarized
in Table 1).
Conditioning intensity and T cell doses. Inbred
mouse strains are variably sensitive to radiation, and
so maximal tolerated doses (primarily delivered in 2
split fractions within a day at\150 cGy/min) differ
from strain to strain. As a general rule, B6 are more re-
sistant that BALB/C mice, and F1 more resistant than
parental strains. Thus, the maximal tolerated total
body irradiation (TBI) dose (ie, that which will allowuniversal survival following transplantation of synge-
neic or T cell-depleted (TCD) allogeneic grafts) is ap-
proximately 900 cGy for a BALB/C mouse relative to
1500 cGy for a B6D2F1 mouse. Generally, the higher
the TBI dose, the earlier and greater the intensity of
the inflammatory arm of GVHD [14]. By contrast,
BMT models utilizing low TBI doses and high donor
T cell doses will result in GVHD dominated by later
onset T cell-dependent pathology. This is particularly
important when studying inflammatory mediators of
GVHD, as inhibitors may have little effect in BMT
models utilizing low TBI and high donor T cell doses,
potentially giving rise to false negative results. Con-
versely, this system may be ideally suited to studying
inhibitors of T cell effector function. BMT models
using non-TBI-based conditioning have been limited,
primarily because of the ease of TBI delivery and its
clear clinical relevance. Nevertheless, cyclophospha-
mide, fludarabine, and busulphan can be delivered in
mouse systems, and this may become important to
model clinical nonmyeloablative transplantation.
Certainly, the addition of these agents to TBI in mouse
models can cause a dramatic enhancement of GVHD
severity and alteration of effector pathways [15].
Models of acute versus chronic GVHD (aGVHD,
cGVHD). Unlike aGVHD models, the induction of
clinically relevant cGVHD in BMT models using
(nonmutated) inbred strains has been challenging. Per-
haps the most relevant is the B10.D2/ BALB/C sys-
tem, originally described as a model of scleroderma in
which grafts are transplanted following sublethal (600
cGy) doses of TBI [16,17]. In our experience, a similar
and more penetrate spectrum of disease also develops
using lethal TBI doses in conjunction with low dosesTable 1. Commonly Used Mouse Models of BMT
Donor Host Usual TBI Dose (cGy) GVHD Targets T cell Dependence Lethality
Acute GVHD models
B6 (B6  DBA/2)F1 1100-1500 I, II, mHAs CD4 (±CD8) Major
B6 BALB/c 900 I, II, mHAs CD4 (±CD8) Major
BALB/c B6 1100 I, II, mHAs CD4 (±CD8) Major
B6 bm1 1100 I CD8 Minimal
B6 bm12 1100 II CD4 Minor
C3H.SW B6 1100 mHAs CD8 Minimal
B6 BALB/b 900 mHAs CD4 Major
B10.D2 DBA/2 1000 mHAs CD4 Major
DBA/2 B10.D2 1000 mHAs CD8 Minor
B10.BR CBA 1100 mHAs CD8 Major
Chronic GVHD models
B10.D2 BALB/c 600-900 mHAs CD4 Minor
LP/J B6 1100 mHAs CD4 Minor
DBA/2 B6D2F1 Nil I, II, mHAs CD4 Minor
B6 (B6  BALB/c)F1 Nil I, II, mHAs CD4 Minor
BALB/c (BALB/c  A)F1 Nil I, II, mHAs CD4 Minor
Donor and host strains used in common BMT models, usual total body irradiation (TBI) doses (delivered in two split doses on a single day at
\150 cGy/min), target GVHD antigens—MHC class I (I), MHC class II (II)—or minor HA (mHA), T cell dependence of subsequent
GVHD (CD4 and/or CD8), and intensity of GVHD lethality (Major $50% mortality, Minor 5 10% to 50% mortality, Minimal 5
\10% mortality) over 6 weeks. TBI doses and lethality will differ depending on recipient pathogen load/animal facility.
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the LP/J/ B6 system, which also induces profound
scleroderma [18]. The DBA/2 / B6D2F1 and
BALB/c/ (BALB/c  A) F1 models (without condi-
tioning) induce antibody-dependent lupus nephritis
[19-21]. The B6/ B6 x BALB/C F1 model (without
conditioning) has been described [22] as inducing
aGVHD before switching to a chronic (lupus nephri-
tis) form thereafter. Unfortunately, these lupus models
have only limited relevance to clinical cGVHD. Com-
mon to these models is CD4-dependent GVHD in the
absence of a significant inflammatory milieu, together
with limited CD8-dependent cytotoxicity. Subsequent
models using MHC-deficient hosts or perforin defi-
cient donors have also been decribed [23,24].
Use of knockout and transgenic mice. Perhaps
the clearest advances in transplant immunology have
come about through the use of mutant animals as
BMT donors or recipients. Although there are some
caveats to the use of these mice (predominantly con-
trolling for developmental abnormalities), their use
allows elucidation of specific cell populations or mole-
cules therein on alloreactive responses that cannot be
achieved by other means. Recently, models have
been developed using immunodeficient mice that per-
mit engraftment of human hematopoietic cells. This
allows the screening of various drugs on human leuke-
mia in vivo and also permits the study of ‘‘humanized’’
reagents in vivo. These animals also develop also de-
velop xenogeneic GVHD if human T cells and APC
are engrafted, although the ineffective cognate interac-
tion between host (mouse) APC and donor (human) T
cells and vice versa [25] does present limitations as
a disease model.
IMAGING GRAFT-VERSUS-HOST REACTIONS IN LIVING
ANIMALS
GVHD and graft-versus-tumor (GVT) reactions
are complex biologic processes that require in vivo
modeling for the greatest understanding. Murine
models have been extremely effective because of the
understood genetics of many different mouse strains
that are available for evaluation, as well as the similarity
between murine GVHD and the human counterpart.
Models across both major and minor histocompatibil-
ity mismatches have been well established in the liter-
ature. Typically, the endpoint of experimental studies
is animal survival, weight loss, and gross symptoms
such as diarrhea, hunchback, and fur ruffling, which
are used for evaluating GVHD progression and sever-
ity. In addition, pathologic scoring systems have been
established for assessing quantitatively the degree of
GVHD severity; however, these latter assays require
animal sacrifice and cannot be performed serially. To
overcome these limitations, we have used novel con-
cepts of bioluminescent-based imaging to trackdonor-derived cell populations in murine models [26].
The basis of in vivo bioluminescence imaging (BLI) is
to track cell populations that have been modified to ex-
press a bioluminescent marker gene. A number of bio-
luminescent molecules are available for such purposes.
In the majority of studies, the North American firefly
luciferase (luc) gene has been utilized because of
well-characterized properties, as well as the use of
a known substrate, namely luciferin, for generating
light. In this ATP, magnesium and oxygen-dependent
reaction luciferin is oxidized, resulting in the emission
of a single photon of light. This light can be captured
using sensitive CCD cameras to create an image of
the light emission over time [27]. The specific advan-
tages of this approach are that the approach is noninva-
sive, quantitative, and can be performed serially in
individual animals. Therefore, far fewer numbers of
animals are required, and the bioluminescent signals
can be used as guides to further assess the biologic pro-
cesses at specific times and in special orientations.
We have utilized this approach of BLI to model
GVHD (Figure 1) [28]. A particular challenge has
been to introduce the luciferase gene into cell popula-
tions of interest. Luc expression can be accomplished
using cell transfer techniques; however, it is laborious
and poorly reproducible. To overcome this limitation
we have generated transgenic mouse strains that con-
stitutively express the firefly luciferase driven by the
chicken beta actin promoter [29]. To further enhance
utility of the model system luc has been coupled to
green fluorescence protein (GFP) to create a dual bio-
luminescent and fluorescent based imaging system.
Using these transgenic animals, any cell population
of interest can be isolated and used as a donor cell pop-
ulation. We have tracked both conventional CD4 and
CD8 cells, as well as regulatory T cells using this sys-
tem [28,30].
Figure 1. Experimental Design: Lymphocytes from a Transgenic
donor are adoptively transferred into recipient mice that are imaged
serially to analyze the trafficking of the infused labeled donor cell.
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initially seen within 24 hours following adoptive trans-
fer in secondary lymph nodes including Peyer’s
patches, mesenteric lymph nodes, and the spleen.
There these cells undergo rapid replication and upre-
gulate certain important molecules such as a4b7 and
other chemokine receptors, which allow entry into
GVHD target organs. Between days 3 and day 5, do-
nor-derived alloreactive cells are primarily located in
nodal sites and then leave these sites. CD4 cells appear
to infiltrate first, followed by CD8 cells. At subsequent
time points the proliferating alloreactive T cells mi-
grate out of these areas into GVHD target organs
such as the skin, liver, and gut. A major question is to
what are the requirements at these nodal sites for
GVHD induction. We have attempted to block
GVHD pathology by adding various monoclonal anti-
bodies that block entry into GVHD target organs such
as MADCAM1 or L-selectin. Both of these molecules
are known to be required for entry into secondary
lymph nodes. Using this approach, GVHD could
only be blocked if the addition of monoclonal anti-
bodies (mAb) was accompanied by splenectomy. In
addition, further studies developing genetic strains of
animals that were devoid of either Peyer’s patches or
lymph nodes also indicated that there was redundancy
in the activation sites such that the spleen could
compensate for a loss in these other priming sites.
Therefore, blocking entry of T cells into GVHD entry
sites is unlikely to be a practical approach for control
of GVHD because splenectomy was also required
(Beilhack et al., submitted).
Additional approaches have been explored includ-
ing the addition of regulatory T cell populations, as
well as developing T cells that lack the ability to induce
GVHD because of their isolation and manipulation in
culture. CD41CD251FoxP1 regulatory T cells (Treg)
have been particularly effective in blocking GVHD
pathophysiology [31]. In this setting, Treg are capable
of homing to many of the same sites as conventional
T cells, yet appear to block conventional T cell prolif-
eration at these sites. The timed addition of Treg 48
hours prior to conventional CD4 and CD8 cells allows
for a significant reduction in cell dose, which could
have practical clinical implications [30]. The mecha-
nism of action of regulatory T cells is not known
with certainty; however, they appear to require hom-
ing to secondary lymph node sites because isolation
of Treg, which express CD62L, are much more effec-
tive in vivo than their CD62L2 counterparts, which
are both functional in vitro [32,33]. These studies pro-
vide important insights into the biologic basis of
GVHD induction and also clues to the development
and strategies for control of GVHD in the clinic.
Other promising approaches to enhancing GVT
without GVHD includes the isolation of certain cell
populations that lack GVHD inducing potential.Such examples could include the use of ex vivo culture
cytokine-induced killer cells [34] or the isolation of
memory CD4 cells [35,36], which appear to have
much less GVHD-inducing potential compared to na-
ive CD4 cells. In addition, the isolation of specific T
cell populations that are cytolytic to tumor cells yet
not to normal host tissues also have great promise in
the clinical application of enhancing GVT without
GVHD [37].
These bioluminescent models also demonstrate
that the current approach to GVHD control may be
limited by assessing the availability of drugs to block
GVHD once it has already been clinically established.
Clearly, important events have occurred at nodal tis-
sues that allow these T cells to become activated and
then infiltrate GVHD target organs, and additional
methodologies are required to develop strategies to
image T cell activation and predict GVHD induction
in the clinic.
MOUSE MODELS OF GVL: PROMISE AND PITFALLS
The concept of leukemia/tumor destruction by the
immune system was originally envisioned by Ehrlich
and later refined by Burnet [38]. Clinical observation
of such a process was made by Coley [39], who noted
regression of tumors in patients that developed infec-
tions. The seminal demonstration of superior leuke-
mia elimination by adoptive transfer of allogeneic
cells than by syngeneic cells was made by Barnes
et al. [40] employing murine models nearly 50 years
ago. This was attributed to an immunologic reaction
by the donor cells against the nonself-host type
leukemia. Barnes noted that extrapolation of this
observation from mouse to man for treatment of leuke-
mia might be possible under certain contexts. Progress
in clinical hematopoietic stem cell transplantation
(HSCT) made it increasingly obvious that although
the intensity of the conditioning regimen was impor-
tant, reconstitution of immune cells from the donor
graft is also critical for optimal leukemia/tumor elimi-
nation: a process called GVL/tumor effect, a term first
used in murine models [41]. It is now widely ap-
preciated that GVL effect following allogeneic HCT
is the most potent and clinically successful form of im-
munotherapy [42]. The observation of the tight link
between GVHD and GVL, their temporal association,
and that lymphohematopoietic tissue is the primary
target of GVH reaction made from mouse models
[43]. These models were also critical for the initial
demonstration of the possibility for separation of
GVHD from GVL [44]. Mouse models thus have
been pivotal in making the early and fundamental ob-
servations on the presence and potency of both
GVHD and GVL. Other models, too, such as the ca-
nine, nonhuman primate, and rat models, have and
continue to play an important roles in studying the
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the presence of well-characterized in-bred strains,
availability of knock-out and transgenic animals, easy
availability of reagents, and the relative low cost have
made mouse models the most utilized systems for in-
vestigating the mechanisms of GVL responses. This
review will briefly discuss some of the most commonly
used mouse models of GVL, the recent insights
gained, and the potential pitfalls. Additionally, it is im-
portant to note that the caveats that are applicable to
studying GVHD in these mouse models are also
germane to GVL, which were reviewed earlier in the
article.
Several strain combinations of mice and a variety of
tumors have been utilized to analyze GVL. They can
be broadly categorized into MHC disparate models
(BALB/c or FVB/ B6, B6/ AKR), parent/ F1
(B6/ B6D2F1), single MHC class I or II disparate
(B6 / B6bm1 and B6 / B6bm12, respectively) and
MHC matched but minor histocompatibility antigen
disparate strains that are either dependent on CD81
T cells (C3H.SW / B6, B10.BR / CBA/J) or
CD41 T cells (B10.D2 / BALB/c and B6 /
BALB.B) for GVH reaction. A variety of murine leuke-
mia/lymphoma cell lines that exhibit the classic 6 hall-
marks of cancer and have spontaneously evolved
(C1498, A20, and BCL-1) or viral or chemically trans-
duced (MBL, MMB3.19, p815, EL-4), and are synge-
neic to recipient animals and have been utilized [45].
In these models small numbers of leukemic cells
are infused at the time of transplant or a few days pre-
ceding HSCT to mimic minimal residual disease. In
a few studies, leukemic cells are infused days after
HSCT. The HSCT protocols, conditioning regimen
(type and intensity: various doses of radiation are
most commonly employed), the source and purity of
T cells (spleen, lymph node or BM), vary between
the studies.
It is important to note that the variations in strains
or tumors of the HSCT protocols can cause significant
alterations in the outcomes of the studies. Neverthe-
less, recent studies utilizing the above models have en-
hanced our understanding of GVL responses. For
example, studies have suggested that depending on
the model and protocol, cytokines that favor either
Th1 or Th2 polarization can preserve GVL responses
[46]. Data also showed that cognate interactions be-
tween T cells and tumors and T cell cytotoxic (CTL)
pathways are critical for GVL [47]. Studies with donor
T cells that are deficient in specific CTL effector func-
tions (perforin, TRAIL, FasL, TNFR1, or TNF-a) or
by retrovirus expressing chronic or blast crisis phase
CML resistant to specific T cell effector pathway
have deepened our understanding of the GVL effector
mechanisms [47,48]. Recent reports have demon-
strated a potentially exciting prospect for separating
GVHD from GVL by utilizing subsets of T cellsthat are polyclonal. Memory T cell subsets or addition
of natural or adaptive regulatory T cells from naı¨ve do-
nor have been shown to preserve GVL despite reduc-
ing GVHD [31,49]. Novel immune cell subsets other
than donor T cells—NK, NKT, and host dendritic
cells—have been shown to modulate GVL [50-52].
Several reagents that alter T cell trafficking, costimu-
lation, or survival have shown promise in these models
[53]. Recent experimental data from mouse models
have also enhanced our understanding of the role of
immunodominant epitopes, epitope spreading, the
impact of mixed chimerism, antileukemia effects of
DLI, the importance of alloantigens and crosspresen-
tation on professional antigen presenting cells in
GVL [54-56]. These studies have thus collectively
provided for novel perspectives in understanding the
overall framework of GVL responses.
Despite the long track record and the promise of
these models in studying GVL mechanisms, it is im-
portant to consider some caveats before extrapolating
the observations to human context [53]. First, as noted
above, results might vary depending on the type of
HCT protocol, the timing, and dose of leukemia in-
duction. Second, the immune responses in inbred
mice that are housed under sterile conditions and are
transplanted without upfront immunosuppression
might not reflect those following alloHCT in outbred,
immunosuppressed humans. Third, the tumor cell
lines that are commonly utilized, despite exhibiting
the classic hallmarks, show variability in subcloning ef-
ficiency and outgrowth of dominant clones that might
likely alter the nature, immunogenicity, and density of
relevant antigens. Moreover, the immune repertoire of
leukemia and lymphomas that develop in these models,
unlike in humans, is more homogenous, as they had
not been sculpted by the process of immunoediting
[57]. Fourth, the kinetics of tumor growth and allo-re-
sponses in most mouse models is rapid, and there are
no models that closely reflect chronic leukemia and
cGVHD in humans.
In summary, murine model systems have provided
a wealth of sound experimental data, which, when in-
terpreted with appropriate caveats, are highly instruc-
tive for understanding the biology of GVL.
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